Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.

Journal Article (Journal Article)

BACKGROUND: Recombinant adenovirus serotype 5 (rAd5)-vectored HIV-1 vaccines have not prevented HIV-1 infection or disease and pre-existing Ad5 neutralizing antibodies may limit the clinical utility of Ad5 vectors globally. Using a rare Ad serotype vector, such as Ad35, may circumvent these issues, but there are few data on the safety and immunogenicity of rAd35 directly compared to rAd5 following human vaccination. METHODS: HVTN 077 randomized 192 healthy, HIV-uninfected participants into one of four HIV-1 vaccine/placebo groups: rAd35/rAd5, DNA/rAd5, and DNA/rAd35 in Ad5-seronegative persons; and DNA/rAd35 in Ad5-seropositive persons. All vaccines encoded the HIV-1 EnvA antigen. Antibody and T-cell responses were measured 4 weeks post boost immunization. RESULTS: All vaccines were generally well tolerated and similarly immunogenic. As compared to rAd5, rAd35 was equally potent in boosting HIV-1-specific humoral and cellular immunity and responses were not significantly attenuated in those with baseline Ad5 seropositivity. Like DNA, rAd35 efficiently primed rAd5 boosting. All vaccine regimens tested elicited cross-clade antibody responses, including Env V1/V2-specific IgG responses. CONCLUSIONS: Vaccine antigen delivery by rAd35 is well-tolerated and immunogenic as a prime to rAd5 immunization and as a boost to prior DNA immunization with the homologous insert. Further development of rAd35-vectored prime-boost vaccine regimens is warranted.

Full Text

Duke Authors

Cited Authors

  • Fuchs, JD; Bart, P-A; Frahm, N; Morgan, C; Gilbert, PB; Kochar, N; DeRosa, SC; Tomaras, GD; Wagner, TM; Baden, LR; Koblin, BA; Rouphael, NG; Kalams, SA; Keefer, MC; Goepfert, PA; Sobieszczyk, ME; Mayer, KH; Swann, E; Liao, H-X; Haynes, BF; Graham, BS; McElrath, MJ; NIAID HIV Vaccine Trials Network,

Published Date

  • May 2015

Published In

Volume / Issue

  • 6 / 5

PubMed ID

  • 26587311

Pubmed Central ID

  • PMC4648371

International Standard Serial Number (ISSN)

  • 2155-6113

Digital Object Identifier (DOI)

  • 10.4172/2155-6113.1000461


  • eng

Conference Location

  • United States